← Browse by Condition
Medical Condition

hodgkin lymphoma

Total Trials
12
Recruiting Now
12
Trial Phases
Phase 1, Phase 3, Phase 4

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — hodgkin lymphoma Clinical Trials

How many clinical trials are currently recruiting for hodgkin lymphoma?
ClinicalMetric currently tracks 12 actively recruiting clinical trials for hodgkin lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hodgkin lymphoma?
hodgkin lymphoma research spans Phase 1 (3 trials), Phase 2 (5 trials), Phase 3 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hodgkin lymphoma clinical trial?
Eligibility criteria for hodgkin lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
1
Top Sponsors
University of Wisconsin, Madison 1 trial
Shanghai Junshi Bioscience Co., Ltd. 1 trial
Marker Therapeutics, Inc. 1 trial
Takeda 1 trial
Masonic Cancer Center, University of Minnesota 1 trial

Recruiting Clinical Trials

NCT02508038 Phase 1
Recruiting
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Enrollment
22 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT06170489 Phase 3
Recruiting
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Enrollment
185 pts
Location
China
Sponsor
Shanghai Junshi Bioscience Co....
View Trial →
NCT05798897 Phase 1
Recruiting
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Enrollment
79 pts
Location
United States
Sponsor
Marker Therapeutics, Inc.
View Trial →
NCT06831370 Phase 4
Recruiting
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Enrollment
124 pts
Location
India
Sponsor
Takeda
View Trial →
NCT03125642 Phase 2
Recruiting
Auto Stem Cell Transplant for Lymphoma Patients
Enrollment
150 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT06812858 Phase 2
Recruiting
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Enrollment
83 pts
Location
Kazakhstan, Russia
Sponsor
St. Petersburg State Pavlov Me...
View Trial →
NCT07793006
Recruiting
New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
Enrollment
500 pts
Location
Malawi
Sponsor
Indiana University
View Trial →
NCT06580002 Phase 2
Recruiting
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Enrollment
75 pts
Location
United States
Sponsor
University of California, Irvi...
View Trial →
NCT07623850 Phase 1
Recruiting
A Phase I Study of JLM019 Injection
Enrollment
115 pts
Location
China
Sponsor
Jecho Biopharmaceuticals Co., ...
View Trial →
NCT06059391 Phase 2
Recruiting
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment
216 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT06203652
Recruiting
The Pathogenesis and Prognostic Factors of Lymphoma
Enrollment
2,000 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →
NCT05615636 Phase 2
Recruiting
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Enrollment
36 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

non hodgkin lymphoma (8) acute myeloid leukemia (2) acute lymphoblastic leukemia (2) myelodysplastic syndrome (2) myeloproliferative syndrome (1) rhabdomyosarcoma (1) ewing sarcoma (1) primitive neuroectodermal tumor (1) osteosarcoma (1) neuroblastoma (1) non hodgkin lymphoma adult (1) non hodgkin lymphoma refractory (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology